EPCAM and breast cancer: Compared to the original tumor, PDX257S exhibited a significant three‐fold increase in mutational burden, involving more oncogenic drivers, along with elevated expression of EpCAM, a recognized marker for cancer stemness associated with a more aggressive subtype of BC tumor [19, 20].